CUBE vs SGMO · P/E 25, rev $1.07B vs rev $57.8M
CubeSmart (CUBE) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the CUBE and SGMO stock pages for the full models.
Not investment advice.